Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1512

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 1512
---
 current
interest rates available for debt with similar terms and maturities are substantially the same.

The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).

The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:

Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.

    F-10

JUPITER
NEUROSCIENCES, INC.

NOTES
TO FINANCIAL STATEMENTS

December
31, 2024 and 2023

Note
2 – Significant Accounting Policies, continued

Fair
Value of Financial Instruments and Fair Value Measurements, continued

The
following table represents the Company’s financial instruments that are measured at fair value on a recurring basis at each reporting
period for each fair value hierarchy level:

Schedule
of Fair Value Hierarchy Level
Financial Instruments

    Derivative
                                            Liability December
                                            31, 2024  
    Derivative
                                            Liability December
                                            31, 2023 
  
    Level I 
    $-  
    $- 
  
    Level II 
    $-  
    $- 
  
    Level III 
    $-  
    $1,505,398 
  
    Total 
    $-  
    $1,505,398 

Also
see Note 5 - Convertible Debt and Derivative Liability.

Derivative
In